The documents on this page include VHA Pharmacy Benefits
Management (PBM) and Medical Advisory Panel (MAP) Criteria for Use documents.
|
Need information on Portable Document Format,
PDF? All documents are in PDF format unless
specified |
|
Acamprosate, Criteria
for Use |
|
Adefovir, Criteria
for Use |
Agalsidase,
Criteria for Non-Formulary Use |
Alatrofloxacin/Trovafloxacin, Criteria for Non-Formulary Use |
Alemtuzumab,
Criteria For Non-Formulary Use
|
Alpha-Adrenergic
Blockers in the Management of Patients with HTN (ALLHAT)
|
Azacitidine, Criteria for Use |
Clinically
Uroselective Alpha Blockers, Criteria for Non-Formulary Use
|
Combination
Alpha-Blocker & Finasteride Therapy for BPH, Criteria for Use |
Angiotensin II Receptor
Antagonists (AIIRAs), Criteria for Use
|
Antiemetic, Criteria for Use |
Antiviral Agents for Influenza, Criteria For Use |
Becaplermin, Criteria for Non-Formulary
Use
|
Topical Anesthesia for Surfaces of the Nasopharynx, Oropharynx, Laryngotracheal Region and Airway, Criteria for Use |
Beta-Adrenergic
Blockers, Criteria for Use
|
Biologics for Psoriasis, Criteria for Non-Formulary
Use (Updated) |
Buprenorphine Criteria for Use
|
Cholinesterase Inhibitor,
Criteria for Use |
Cilostazol, Criteria for Use |
Cinacalcet, Criteria for
Non-Formulary Use
|
Clopidogrel, Criteria for Use
|
Dihydropyridine Calcium
Antagonists, Criteria for Use
|
Drotrecogin
Alfa, Criteria for Use
|
Duloxetine, Criteria for Non-Formulary
Use
|
Enfuvirtide, Criteria for Use
|
Enoxaparin, Criteria for Use in
Mechanical Heart Valve Patients
|
Erlotinib, Criteria for
Non-Formulary Use |
Erythropoietin Criteria for Use for Hepatitis C, Criteria for Use |
Eszopiclone, Criteria for Non-Formulary Use |
Exenatide, Criteria for Non-Formulary Use |
Ezetimibe Criteria for Non-Formulary Use |
Fluoroquinolone ,Criteria for Use |
Fluva-Prava-Atorva-Rosuv Criteria for Non-Formulary
Use |
Fondapariux, Criteria for Use |
Gabapentin, Criteria for Use |
Gefitinib Criteria for Non-Formulary Use |
GCSF Criteria for Use for Hepatitis C, Criteria for Use |
Fuzeon, Criteria for Use |
HMGs, Criteria for
Non-Formulary Use in Patients Receiving Protease Inhibitor Therapy
|
Highly Teratogenic Retinoids and High-dose Vitamin A, Criteria for Use |
Imatinib,
Criteria for Use
|
Initiating Therapy In Early Parkinson’s
Disease, Criteria for Use |
Insulin
Glargine, Criteria for Non-formulary Use
|
Leflunomide and Biologic DMARDs for Rheumatoid Arthritis, Criteria for use |
Leukotriene Inhibitor,
Criteria for Use
|
Leuprolide Implantable (Viadur)
Criteria for Non-Formulary Use
|
Levetiracetam, Criteria for Use
|
Linezolid, Quinupristin-Dalfopristin, and Daptomycin,
Criteria for Use
|
Memantine, Criteria for Use |
Meperidine, Criteria for Use |
Multiple Sclerosis, Use of Disease Modulating Agents in MS
|
Omacor, Criteria for Non-formulary Use
|
Omalizumab, Criteria for Non-Formulary
Use |
Orlistat - Criteria for Use |
Oxycodone
CR,
Criteria for use,
Treatment
Algorithm
|
Pantoprazole I.V. Criteria
for Use Pantoprazole I.V. Literature Review |
Pegaptanib, Criteria for Non-Formulary
Use
|
Pegfilgrastim, Criteria for Non-Formulary
Use
|
Pharmacologic Management of Primary Pulmonary Hypertension,
Criteria for Use |
Pharmaceutical Selection of Antiplatelet Therapy in Cerebrovascular Disease, Criteria for Use
|
Phosphate Binder, Criteria for
Non-Formulary Use |
Pramlintide Criteria for
Non-Formulary Use |
Proton Pump Inhibitors, High-dose,
Criteria for Use |
Quinine Sulfate, Criteria for Non Formulary
Use
|
Appendix I (Noctural
Leg Cramps)
|
Ramipril, Criteria for Non
Formulary Use
|
Risperidone Long-Acting, Criteria for Use |
Sibutramine - Criteria for Use |
Synvisc and
Hyalgan, Criteria for Non-Formulary Use
|
Tegaserod, Criteria for Non-Formulary Use |
Teriparatide, Criteria for
Non-Formulary Use |
Tiotropium, Criteria for Non-Formulary
Use |
Tipranavir, - Criteria for Use |
TZD (Thiazolidinediones,
Rosiglitazone, Pioglitazone) Criteria for Use
|
Ziprasidone IM Criteria for
Non-Formulary Use |
Ziprasidone, Criteria for Use
|